{"id":7807,"date":"2016-03-05T17:42:27","date_gmt":"2016-03-05T16:42:27","guid":{"rendered":"https:\/\/www.realadvokatbyra.se\/?p=7807"},"modified":"2026-08-18T15:24:37","modified_gmt":"2026-08-18T13:24:37","slug":"life-science-partners-ysios-capital-sunstone-capital-and-flerie-invest","status":"publish","type":"post","link":"https:\/\/www.realadvokatbyra.se\/en\/life-science-partners-ysios-capital-sunstone-capital-and-flerie-invest\/","title":{"rendered":"Real advised a conglomerate of investors in their investment in OxThera AB."},"content":{"rendered":"\n
\n

<\/p>\n<\/div>\n\n\n

OxThera AB raised EUR 32,000,000 to complete development of Oxabact\u00ae. Real advised the co-leaders of the investment, Life Science Partners (Netherlands), Ysios (Spain), Sunstone (Denmark) and Flerie (Sweden), who invested in addition to the current shareholders Kurma Partners and IdInvest (France), Stiftelsen Industrifonden and Brohuvudet (Sweden). The investment was made through the subscription of a new class of shares. Real advised the clients on structuring and ownership issues. The transaction was completed in Q4 2016.<\/p>\n

OxThera is a Swedish biopharmaceutical company devoted to developing drugs for the treatment of primary hyperoxaluria. OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline; Oxabact\u00ae\u00a0for the treatment of\u00a0primary hyperoxaluria, and Oxazyme\u00ae, an oxalate decarboxylase, for\u00a0treatment of\u00a0dietary hyperoxaluria and\u00a0prevention of kidney stones. Oxabact\u00ae\u00a0holds orphan drug designations in the EU and the US for the treatment of Primary hyperoxaluria, and in EU for treatment of Short Bowel Syndrome (SBS).<\/p>\n

The firm\u2019s team consisted primarily of Partner Patrik Lilieblad and Associates Mikaela Rennerfelt and Frida Lindberg.<\/p>\n\n\n

\n

Contact<\/h4>\n\n\n\n